Download by
Scanning QR Code
No Stock Yet
Teichi Pharmaceutical: Received a letter of condolence from the Ministry of Industry and Information Technology
Glonhui, January 19, 丨 Teyi Pharmaceutical announced that the company made every effort to produce and supply ibuprofen tablets and acetaminophen tablets, received recognition from the government, and received a “letter of condolence” from the other party.
Teyi Pharmaceutical (002728.SZ) is forecasting an increase. Net profit of 173 million yuan to 183 million yuan in 2022 is expected to increase 36.31% to 44.19% year-on-year
According to the Zhitong Finance App, Teyi Pharmaceutical (002728.SZ) released its 2022 annual performance forecast. The net profit attributable to shareholders of listed companies for the full year is 173 million yuan to 183 million yuan, an increase of 36.31% to 44.19% over the previous year. During the reporting period, net profit attributable to shareholders of listed companies and net profit after deducting non-recurring profit and loss increased significantly compared to the same period of the previous year. The main reason was that since the third quarter, the company adjusted its marketing strategies and plans, increased its market development and promotion efforts, and achieved good results. In particular, in the fourth quarter, after the epidemic was liberalized, the company increased its epidemic prevention
Teyi Pharmaceutical: Net profit is expected to increase 36%-44% year-on-year in 2022
The pharmaceutical sector continues to decline, and many stocks are down more than 5%.
The traditional Chinese medicine sector continued to decline, with Shanghai Kaibao falling more than 12%
Teyi Pharmaceutical will release 5 million tablets of antipyretic drugs to the Jiangmen market
Gelonhui, December 22丨According to Te Yi Pharmaceutical, Teyi Pharmaceutical will join hands with the prevention and control material support team of the Jiangmen Covid-19 Prevention and Control Command Office in two batches on December 23 and 26 to launch a total of 3 million ibuprofen tablets (30,000 bottles) and 2 million paracetamol tablets (20,000 bottles) on the market through targeted, unbundled, limited, and limited-price sales methods.
Teyi Pharmaceutical Ties Up With Educational Institution for Anti-Cough Tablets Study
05:01 AM EST, 12/21/2022 (MT Newswires) -- Teyi Pharmaceutical Group (SHE:002728) partnered with Guangzhou Institute of Respiratory Health to study the efficacy of Zhikebao tablets as a treatment for
Concept tracking | There is a “rush to buy” acetaminophen tablets and industry chain companies are expected to benefit from a sharp rise in sales of fever-reducing analgesic drugs (with concept stocks)
The Zhitong Finance App learned that with the full liberalization of epidemic prevention and control, the number of infected people across the country has skyrocketed, setting off a “rush to buy” acetaminophen fever-reducing drugs at one point. Recently, the joint prevention and control mechanism of the State Council issued home treatment guidelines and common medication references for people infected with COVID-19. Commonly used drugs were listed based on seven symptoms such as fever, dry throat, and cough and phlegm. Among them, acetaminophen was included as a drug for symptoms of fever. Northeast Pharmaceutical (000597.SZ) has 4 plates in 6 days, Teyi Pharmaceutical (002728.SZ) has increased 1.05 times in the past two months, Xinhua Pharmaceutical (000756.SZ) 1
Teyi Pharmaceutical: Signed an entrustment agreement with Guangzhou Respiratory Health Research Institute
Gelonhui, December 20, 丨 Teyi Pharmaceutical announced that it recently signed a “Commissioning Agreement on the Pharmacological Mechanism and Substance Basis Research on the Pharmacological Mechanism and Substance Basis of Cough Relief Tablets for Treating Cough and Lung Inflammation after Influenza Virus Infection” with the aim of increasing its indications for airway inflammation, cough and phlegm increase caused by respiratory viral infections, and further enhancing product brand and marketing capabilities through research on the pharmacological mechanism and material basis of cough suppressants for treating cough and lung inflammation after influenza virus infection..
Teyi Pharmaceutical: It is making every effort to produce ibuprofen tablets to guarantee market demand
Loading...
No Stock Yet